Envisagenics

Envisagenics employs Artificial Intelligence (AI) and Machine Learning (ML) to develop RNA therapeutics, focusing on the discovery and validation of new drug targets through its proprietary software platform, SpliceCore. SpliceCore utilizes RNA sequencing data combined with advanced AI/ML algorithms to enhance the process of target identification, testing, and validation. The platform boasts a search space 250 times larger than traditional methods and demonstrates a 78% success rate in experimental validation of its discovered targets. Additionally, SpliceCore includes a specialized branch, SpliceIOTM, designed to identify tumor-specific neoepitopes that can be targeted with antibody-based modalities. Envisagenics has established strategic collaborations with notable institutions such as Cancer Research Horizons and Queen Mary University of London to advance research in hematopoietic cancers. Furthermore, the company has entered into a research collaboration with Bristol Myers Squibb to apply the SpliceCore AI platform in developing oncology therapeutic candidates.